Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 601–700 of 883

Exploring the binding mechanism of saccharin and sodium saccharin to promoter of human p53 gene by theoretical and experimental methods
Mansourian, M., Mahnam, K., Rajabi, H. R., Roushani, M., & Doustimotlagh, A. H. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1582438 · Cited by 8
Multi-Omic Data Improve Prediction of Personalized Tumor Suppressors and Oncogenes
Sudhakar, M., Rengaswamy, R., & Raman, K. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.854190 · Cited by 8
Tumor Suppressor Genes
Cheng, Y. (2012) · InTech eBooks · doi:10.5772/1337 · Cited by 9
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS)
Bai, F., Zhu, F., Tagen, M., Miller, L. A., Owens, T. S., Mallari, J. P., Derrick, E., Zhang, F., & Stewart, C. F. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2009.10.016 · Cited by 8
p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small moleculesPreprint
Sadagopan, A., Garaffo, N., Chang, H.-J., Schreiber, S. L., Meyerson, M. M., & Gibson, W. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.27.605429 · Cited by 8
Evaluation of involved proteins in colon adenocarcinoma: an interactome analysis.
Valizadeh, Ř., Bahadorimonfared, A., Rezaei–Tavirani, M., Norouzinia, M., & Ardakani, M. I. E. (2017) · Gastroenterology and hepatology from bed to bench. · Cited by 6
Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis
Brunetti, B., de Biase, D., Dellapina, G., Muscatello, L. V., Ingravalle, F., Tura, G., & Bacci, B. (2023) · Animals · doi:10.3390/ani13050899 · Cited by 7
Concepts in B cell acute lymphoblastic leukemia pathogenesis
Garcia, C., Miller, M. D., & Witkowski, M. T. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae015 · Cited by 9
Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia
Khoral, P., Atenafu, E. G., Craddock, K. J., Schimmer, A. D., & Chang, H. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.009 · Cited by 7
Strategy of Hepatic Metabolic Defects Induced by beclin1 Heterozygosity in Adult Zebrafish
Mawed, S. A., He, Y., Zhang, J., & Mei, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041533 · Cited by 7
Low-dose but not high-dose γ-irradiation elicits the dominant-negative effect of mutant p53 in vivo
Ghaleb, A., Roa, L., & Marchenko, N. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.018 · Cited by 8
Doxorubicin induced aggregation of α-synuclein: Insights into the mechanism of drug induced Parkinsonism
Garg, A., & Sinha, S. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112371 · Cited by 7
A Second Career for p53 as A Broad-Spectrum Antiviral?
Harford, J. B. (2023) · Viruses · doi:10.3390/v15122377 · Cited by 7
TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer
Hainaut, P. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_1 · Cited by 10
Self-citation
Mutant p53 Cooperates with Knockdown of Endogenous Wild-Type p53 to Disrupt Tubulogenesis in Madin-Darby Canine Kidney Cells
Zhang, Y., Yan, W., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085624 · Cited by 7
C23 promotes tumorigenesis via suppressing p53 activity
Li, Q., Zhu, Y. Y., Hou, L., Wang, J., Hu, G., Fang, X., Hu, Y., Tao, T., Wei, X., Tang, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11071 · Cited by 7
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7
Integrative Analysis of Cancer Omics Data for Prognosis Modeling
Wang, S., Wu, M., & Ma, S. (2019) · Genes · doi:10.3390/genes10080604 · Cited by 7
Activation-induced cytidine deaminase expression in colorectal cancer.
Li, L., Su, N., Cui, M., Li, H., Zhang, Q., Yu, N., Wu, S., & Cao, Z. (2019) · PubMed Central · Cited by 7
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors
Hsieh, A., Pitarresi, J. R., Lerner, J., Donahue, G., Hsiehchen, D., Rustgi, A. K., & Zaret, K. S. (2020) · Science Advances · doi:10.1126/sciadv.abc4517 · Cited by 7
Adrenocortical tumors and hereditary syndromes
Jeyaraman, K., Concolino, P., & Falhammar, H. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2431748 · Cited by 6
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Zhou, D. D.-X., Lord, S. J., Lin, F. P. Y., Cooper, W. A., Zaheed, M., Simes, R. J., John, T., & Lee, C. K. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108891 · Cited by 6
TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC
Feng, H., Xu, H., Shi, X., Ding, G., Yan, C., Li, L., Jian, Z., Yang, X., Guo, H., Feng, L., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807147 · Cited by 6
Head and Neck Squamous Cell Carcinoma: Prognosis using molecular approach
Mazumder, T. H., Nath, S., Nath, N., & Kumar, M. (2014) · Open Life Sciences · doi:10.2478/s11535-014-0292-3 · Cited by 9
Biallelic TP53 gain of function mutations in rapidly progressing solid tumors
Sande, C. M., Chang, B., Monga, V., Bossler, A., & Ma, D. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.001 · Cited by 6
Association of TP53 gene codon 72 polymorphism with Helicobacter pylori-positive non-cardia gastric cancer in Vietnam
Hà, T. M. T., Le, T. N. U., Nguyen, V. N., & Tran, V. H. (2019) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.11488 · Cited by 6
Investigation on the Genomic Characterization of Uterine Sarcoma for rAd- p53 Combined with Chemotherapy Treatment
Xia, Y., Wang, L., Ma, X., & Li, X. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.305 · Cited by 6
Single loss of a Trp53 allele triggers an increased oxidative, DNA damage and cytokine inflammatory responses through deregulation of IκBα expression
Marruecos, L., Manils, J., Moreta-Moraleda, C., Gómez, D., Filgaira, I., Serafín, A., Cañas, X., Espinosa, L., & Soler, C. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03638-3 · Cited by 6
Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana
Opoku, F., Bedu-Addo, K., Titiloye, N. A., Manu, E. A., Ameh-Mensah, C., & Duduyemi, B. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258543 · Cited by 6
TP53 Mutations in Human Cancers: Selection versus Mutagenesis
Olivier, M., Petitjean, A., de Fromentel, C. C., & Hainaut, P. L. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_1 · Cited by 6
Self-citation
HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis
Al-Azawi, D., Leong, S., Wong, L., Kay, E. W., Hill, A. D. K., & Young, L. S. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.584586 · Cited by 6
Dual guide RNA-mediated concurrent C&G-to-T&A and A&T-to-G&C conversions using CRISPR base editors
Zhao, Y., Li, M., Liu, J., Xue, X., Zhong, J., Lin, J., Ye, B., Chen, J., & Qiao, Y. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.12.055 · Cited by 6
A subregion‐based burden test for simultaneous identification of susceptibility loci and subregions within
Zhu, B., Mirabello, L. J., & Chatterjee, N. (2018) · Genetic Epidemiology · doi:10.1002/gepi.22134 · Cited by 7
Involvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT – Induced pulmonary hypertension in rats
Song, Z.-H., Wang, H., Liu, M., Bai, Y., Wang, Y., & Wang, H. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.03.013 · Cited by 6
Osteosarcoma
Janeway, K. A., Gorlick, R. G., & Bernstein, M. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00022-4 · Cited by 6
TP53 Gene Polymorphisms in Cancer Risk: The Modulating Effect of Ageing, Ethnicity and TP53 Somatic Abnormalities
Denisov, E. V., Nadezhda, V., Nicolay, V., Elena, A., Natalya, N. N., Valentina, A., & Mikhail, I. S. (2012) · InTech eBooks · doi:10.5772/27768 · Cited by 5
Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Jordan, J. J., Menéndez, D., Inga, A., Noureddine, M., Bell, D. A., & Resnick, M. A. (2008) · PLoS Genetics · doi:10.1371/annotation/13bc83be-2345-401d-b953-f1886e9fbdff · Cited by 6
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer
Cirello, V., Colombo, C. M., Tosi, D., Manzo, A., Borghi, M. O., Gianelli, U., Gazzano, G., Ferrero, S., Dionigi, G., Persani, L., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf056 · Cited by 5
Nucleolar control by a non‐apoptotic p53‐caspases‐deubiquitinylase axis promotes resistance to bacterial infection
Chen, P., Chen, Y., Chu, T., Ma, T., Wu, M.-H., Lin, H., Chang, Y., Tan, B. C., & Lo, S. J. (2019) · The FASEB Journal · doi:10.1096/fj.201901959r · Cited by 5
NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis
Zhang, J., Liu, J. J., McGillivray, P. D., Yi, C., Lochovsky, L., Lee, D., & Gerstein, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03758-1 · Cited by 5
Prediction of risk-associated genes and high-risk liver cancer patients from their mutation profile: benchmarking of mutation calling techniques
Patiyal, S., Dhall, A., & Raghava, G. P. S. (2022) · Biology Methods and Protocols · doi:10.1093/biomethods/bpac012 · Cited by 5
Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers
Kastora, S. L., Kounidas, G., Speirs, V., & Masannat, Y. (2022) · Cancers · doi:10.3390/cancers14163854 · Cited by 5
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
Chen, S., Ji, M., Xu, P., & Zhao, W. (2022) · Aging and Cancer · doi:10.1002/aac2.12058 · Cited by 5
Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock‐in (Hupki) mouse genome
Kim, S., Hollstein, M., Pfeifer, G. P., & Nia, A. B. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20683 · Cited by 5
Allelic loss at TP53 in metastatic human endometrial carcinomas
Szewczuk, W., Skomra, D. G., Cybulski, M., Prządka-Rabaniuk, D., Filip, A. A., Jóźwik, M., Olcha, P., Roessner, A., & Semczuk, A. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9278-3 · Cited by 5
Multiple Malignancies in a Child with de novo TP53 Mutation
Woźniak, A. E., Fryer, A. E., Grimer, R. J., & Dowell, H. M. (2011) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.548439 · Cited by 5
An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication
Smardova (1994) · Oncology Reports · doi:10.3892/or_00000073 · Cited by 5
Breast Cancer Detection Using Surface Plasmon Resonance-Based Biosensors
ABSTRACT, C.-W. L. A. C.-C. C. (2012) · CRC Press eBooks · doi:10.1201/b12737-17 · Cited by 5
Traditional Approaches to Molecular Genetic Analysis
Walker, C. J., & Goodfellow, P. J. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_4 · Cited by 5
Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms
Ohmori, Y., Nomura, T., Fukushima, N., Takahashi, F., Iwaya, T., Koeda, K., & Nishizuka, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25718 · Cited by 5
Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern
Li, Y., Chen, B., Lin, X.-Y., Zhang, G.-C., Lai, J., Li, C., Lin, J., Guo, L., Xiao, W., Mok, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830124 · Cited by 5
Study of P53 Gene Mutations as a New Early Diagnostic Markers of Hepatocellular Carcinoma in Egyptian Patients
Elhameed, A. H. A., Abo-Elenein, A., Ibrahim, W., El-kassas, G., & Noweir, M. (2018) · Madridge Journal of Oncogenesis · doi:10.18689/mjo-1000104 · Cited by 5
The mitosis-differentiation checkpoint, another guardian of the epidermal genome
Gandarillas, A., Molinuevo, R., Freije, A., & Alonso‐Lecue, P. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2014.997127 · Cited by 5
Transcription of genes of p53-dependent apoptosis in acute leukaemia
Racay (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000092 · Cited by 5
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
Salama, A. K. S., Wang, V., Macrae, E. R., Park, J.-I., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D. R., Williams, P. M., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00338 · Cited by 4
Aneuploidy as a cancer vulnerability
Cao, J., Liang, C., & Yu, H. (2025) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2025.102490 · Cited by 4
Somatic p53 mutations that are markedly overrepresented in lung cancer confer resistance to reactive oxygen species-induced cell death
Tracewell, M., Karlin, J., Barnada, S. M., McDuffie, E., Scott, C. P., Barta, J. A., & McMahon, S. B. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf027 · Cited by 4
Systematic tracking of coordinated differential network motifs identifies novel disease-related genes by integrating multiple data
Shi, K., Gao, L., & Wang, B. (2016) · Neurocomputing · doi:10.1016/j.neucom.2015.12.120 · Cited by 4
SERS combined with PCR as a potent tool for detecting mutations: a case study of tomato plants
Sen, S., Chalapathi, D., Targolli, J., & Narayana, C. (2022) · RSC Advances · doi:10.1039/d2ra06044b · Cited by 4
KMT2 ( MLL ) family of methyltransferases in head and neck squamous cell carcinoma: A systematic review
Santos, M. E. D. S., Abreu, A. K. D. C., da Silva, F. W. M., Ferreira, E. B., dos Reis, P. E. D., & Ramos, D. D. A. R. (2023) · Head & Neck · doi:10.1002/hed.27597 · Cited by 5
Bibliometric analysis and visualisation of research hotspots and frontiers on omics in osteosarcoma
Wang, X., Cao, X., Dai, Z., & Dai, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05898-w · Cited by 5
Involvement of Promyelocytic Leukemia Protein in the Ethanol-induced Apoptosis in Mouse Embryo Fibroblasts
Wang, L., Yang, J., Cui, W., Shin, Y. K., & Wu, C. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.1067 · Cited by 4
Colorectal cancer in the young
Mitchell, E. P. (2012) · Colorectal Cancer · doi:10.2217/crc.12.55 · Cited by 4
International survey of awareness of genetic risk in the clinical sarcoma community
McBride, K. A., Schlub, T. E., Ballinger, M. L., Thomas, D. M., & Tattersall, M. H. N. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12457 · Cited by 4
Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer
Nguyen, K. V. (2022) · AIMS neuroscience · doi:10.3934/neuroscience.2022010 · Cited by 5
PO2RDF: representation of real-world data for precision oncology using resource description framework
Zhao, Y., Dimou, A., Shen, F., Zong, N., Davila, J. I., Liu, H., & Wang, C. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01314-9 · Cited by 4
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia
Nakagawa, S., Kawahara, K., Okamoto, Y., Kodama, Y., Nishikawa, T., Kawano, Y., & Furukawa, T. (2022) · Cancers · doi:10.3390/cancers14205127 · Cited by 4
Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers
Vu, T., Fowler, A., & McCarty, N. (2023) · Cancers · doi:10.3390/cancers15153792 · Cited by 4
First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene
Yeh, Y., Chang, Y., Ma, C., Huang, C.-W., Tsai, H., Chen, Y., & Wang, J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3878-0 · Cited by 4
Prediction of Colorectal Cancer Driver Genes from Patients’ Genome Data
Abdullah, M.-I., & Muhammad, N. A. N. (2018) · Sains Malaysiana · doi:10.17576/jsm-2018-4712-20 · Cited by 4
Oxidatively generated DNA base modifications: Relation to eustress and distress
Epe, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00018-3 · Cited by 5
Study on X-ray-induced apoptosis and chromosomal damage in G2 human lymphocytes in the presence of pifithrin-α, an inhibitor of p53
Ortenzi, V., Meschini, R., Berni, A., Mancinelli, P., & Palitti, F. (2011) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2011.07.013 · Cited by 4
Systematical Analysis of Cutaneous Squamous Cell Carcinoma Network of microRNAs, Transcription Factors, and Target and Host Genes
Wang, N., Xu, Z.-W., & Wang, K. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.23.10355 · Cited by 4
K-State automaton burst detection model based on KOS: Emerging trends in cancer field
Wu, Q., Zhang, H., & Lan, J. H. (2014) · Journal of Information Science · doi:10.1177/0165551514551500 · Cited by 4
A periodic table for cancer
Epstein, R. J. (2015) · Future Oncology · doi:10.2217/fon.14.315 · Cited by 4
Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers
Xie, Z., Chng, W. J., Tay, K.-G., Liu, S. C., Zhou, J., & Chen, C.-S. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0423-5 · Cited by 4
The Utility of Transgenic Mouse Models for Cancer Prevention Research
Hursting, S. D., Lashinger, L. M., Brown, P. H., & Perkins, S. N. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_18 · Cited by 4
Multivariate Association Analysis with Somatic Mutation Data
He, Q., Liu, Y., Peters, U., & Hsu, L.-I. (2017) · Biometrics · doi:10.1111/biom.12745 · Cited by 4
Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as A Molecular Insight towards Personalized Medicine
Hammam, O. A., Magdy, M., Badawy, M. H., Osili, K. A., Kholy, A. E., & El-Leithy, T. (2017) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2017.100 · Cited by 4
Characterizing genomic differences of human cancer stratified by the TP53 mutation status
Wang, M., Yang, C., Zhang, X., & Li, X. (2018) · Molecular Genetics and Genomics · doi:10.1007/s00438-018-1416-7 · Cited by 4
The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas
Wang, X., Chen, D., & Chen, B. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.04.021 · Cited by 4
Breast Cancer Interaction Network Concept from Mostly Related Components
Azodi, M. Z., Rezaei-Tavirani, M., Bashash, D., Ahmadi, N., & Rostaim-Nejad, M. (2019) · Galen Medical Journal · doi:10.31661/gmj.v8i0.1298 · Cited by 4
TP53 mutations in breast cancer: association with ductal histology and early relapse of disease
Brankovic-Magic, M. V., Jankovic, R. N., Dobričić, J., Borojević, N., Magić, Z., & Radulovic, S. S. (2008) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.2186 · Cited by 4
High-resolution QTL mapping with Diversity Outbred mice identifies genetic variants that impact gut microbiome compositionPreprint
Schlamp, F., Zhang, D. Y., Beltrán, J. F., Cosgrove, E. J., Šimeček, P., Edwards, M. M., Goodrich, J. K., Ley, R. E., Pack, A. I., Churchill, G. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/722744 · Cited by 3
Coarse-Grained Simulations of Phosphorylation Regulation of p53 Autoinhibition
Barethiya, S., Schultz, S., Zhang, Y., & Chen, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00668 · Cited by 3
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 ( PDK1 ) to Promote Proliferation and Migration in Breast Cancer
Ye, Y., Ou, Z., Li, C., Liao, Q., Zeng, Q., Ju, X., Zhang, D., Wei, Y., Zhang, X., Zhang, J., et al. (2025) · Cancer Science · doi:10.1111/cas.70252 · Cited by 3
Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope
Olesinski, E. A., & Bhatt, S. (2025) · Biomedicines · doi:10.3390/biomedicines13123007 · Cited by 4
Loss of BOK increases vulnerability of p53 deficient non-small cell lung cancer cells to ATR inhibition through its role in uridine metabolism
JeanRichard, P., Ananthanarayan, A., Wu, L., Jazaeri, A., Bachmann, D., & Kaufmann, T. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01666-0 · Cited by 3
Immunological Role of TP53 Somatic Mutation Classification in Human Cancers
Fang, J., Yang, Y., Xie, L., & Yin, W. (2023) · Journal of Oncology · doi:10.1155/2023/1904309 · Cited by 3
TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds
Chakraborty, R., Dutta, A., & Mukhopadhyay, R. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03841-6 · Cited by 3
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer
Zhang, G.-J., Pannucci, A., Ivanov, A. A., Switchenko, J. M., Sun, S.-Y., Sica, G. L., Liu, Z.-T., Huang, Y., Schmitz, J. C., & Owonikoko, T. (2025) · Cancers · doi:10.3390/cancers17030446 · Cited by 1
Alterations in TP53 gene – Implications in Tumorigenesis Process and Prognosis in Central Nervous System Cancer
Pessôa, I. A., da Silva, F. P. E., Anselmo, N. P., & de Oliveira, E. H. C. (2014) · InTech eBooks · doi:10.5772/58334 · Cited by 5
Comparative Study of Cellular Tumor Antigen p53 Protein of Fishes and Analysis of its Protein Interaction Network using Computational Approach
Kumari, S., Rasal, K. D., Sundaray, J. K., Nandi, S., & Jayasankar, P. (2015) · Computational Molecular Biology · doi:10.5376/cmb.2015.05.0003 · Cited by 3
Regulatory network of microRNAs and genes in testicular cancer
Zhao, Y., Xu, Z., Wang, N., & Wang, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5043 · Cited by 3
Correlation of P53 Expression with Various Clinicopathological Parameters of Gastric Carcinoma and Its Relationship with Survival
Sankalecha, T. H., Gupta, S., Gaikwad, N., & Ughade, S. N. (2017) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2017.06.707 · Cited by 3
Impact of glutathione S transferases P1 (Ile105Val) variants on the risk of GSTp, phosphorylated c-Jun kinase, and P53 phenotypic expression and their implications on overall survival outcomes in non-small cell lung cancer patients treated with chemotherapy
Pathak, A. K., Husain, N., Shukla, S., Pandey, R. K., Kant, S., & Bala, L. (2022) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2022.111775 · Cited by 3
Cimetidine-Based Cationic Amphiphiles for In Vitro Gene Delivery Targetable to Colon Cancer
Manturthi, S., Bhattacharya, D., Sakhare, K. R., Narayan, K. P., & Patri, S. V. (2022) · ACS Omega · doi:10.1021/acsomega.2c03777 · Cited by 3
Greater expectations: meeting clinical needs through broad and rapid genomic testing
Poveda-Rogers, C., & Morrissette, J. J. D. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1016 · Cited by 3
Thymoma; clinical presentations, pathology, and prognostic factors – a surgery point of view
Hemmati, H. R., & Memarian, M. (2023) · Immunopathologia Persa · doi:10.34172/ipp.2023.40581 · Cited by 3
Tetrahydrocurcumin-induced apoptosis of hepatocellular carcinoma cells involves the TP53 signaling pathway, as determined by network pharmacology
Bao, Z.-C., Ye, Z., Liu, Z., Dai, H., Ren, F., Li, N., Lv, S., & Zhang, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.101174 · Cited by 3

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks